Singapore, 31 December 2021 – Cell therapy firm RxCell Inc. (“RxCell” or the “Company”) plans to apply for regulatory approval in the United States for first-in-human trials to treat age-related retinal degeneration and inherited retinal diseases (“IRDs”) after netting an investment from the Regenosis Gero-Science Fund (the “Fund”).
Age-related macular degeneration accounts for 9 percent of all blindness worldwide and is the most common cause of blindness in developed countries, especially among the elderly aged above 60 years. Globally, it is estimated that 288 million people will suffer from age-related macular degeneration in 2040. [i] IRDs are a group of diseases that can cause severe vision loss or even blindness due to at least one genetic defector disorder. IRDs occur in one in every 2,000 people and are the leading cause of vision loss in people aged between 15 and 45 years of age. [ii] There is no known treatment for dry form advanced macular degeneration and there is no widespread applicable treatment for all IRDs.
In a study published in Stem Cell Research and Therapy on 19 August 2021, scientists from The Agency for Science, Technology and Research (“A*STAR”)’s Institute of Molecular and Cell Biology (“IMCB”), Yong Loo Lin School of Medicine, National University of Singapore (“NUS Medicine”), the Singapore Eye Research Institute (“SERI”) and RxCell successfully transplanted photoreceptors into primates by using allogenic stem cells as source material, thus demonstrating safety and therapeutic potential for future clinical trials. [iii]
To further leverage on RxCell’s clinical grade induced Pluripotent Stem Cell (“iPSC”) line and proprietary hypoimmunogenic iPSC strategy, A*STAR’s IMCB, RXCell, NUS Medicine and SERI have announced on 11 October 2021 their collaboration to setup a joint lab and develop next generation cellular therapeutics forage-related retinal and musculoskeletal diseases. [iv]
RxCellis one of the Fund’s identified targets in its pipeline at inception in May2021. The investment demonstrates the Fund’s commitment in executing its strategy to invest in maturing translational Geroscience technologies with the objective of monetization within three years or more. The Fund aims to provide exposure to highly exclusive investment opportunities for accredited investors.
Edge Capital Asset Management Pte. Ltd. is the appointed investment manager of theFund. Interested parties may refer to https://www.edgecap-am.com/portfolio/regenosis-gero-science-fund.
RxCellis a cell therapy company with clear pipelines of products and next generation products. It has manufactured a Master Cell Bank of induced pluripotent stem cells (iPSC) for allogenic therapy including current Investigational New Drug activities for retinal degenerative disorders. This is the first USFDA-approved induced Pluripotent Stem Cell (“iPSC”) line developed under Current Good Manufacturing Practice (“cGMP”)-compliant conditions including tissue sourcing, manufacturing, testing and storage. More recently, it has developed a novel hypoimmunogenic strategy and made universal iPSC lines that can be used to manufacture differentiated cells for allogenic therapy. It also has a safe harbor patented technology that allows for expressing therapeutic products that can be delivered to target locations for prolonged and sustained delivery of biologics.
In addition, RxCell markets cells and media as well as other associated reagents for academic and drug discovery research though its XCell Science brand(http://www.xcellscience.com/).
[i] WanLing Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-YuCheng, Tien Yin Wong, Global prevalence of age-related macular degenerationand disease burden projection for 2020 and 2040: a systematic review andmeta-analysis, The Lancet Global Health, Volume 2, Issue 2, 2014, Pagese106-e116, ISSN 2214-109X, https://doi.org/10.1016/S2214-109X(13)70145-1.
[ii] CremersFPM, Boon CJF, Bujakowska K, Zeitz C. Special Issue Introduction: Inherited RetinalDisease: Novel Candidate Genes, Genotype–Phenotype Correlations, andInheritance Models. Genes. 2018; 9(4):215. https://doi.org/10.3390/genes9040215
[iii] Lingam,S., Liu, Z., Yang, B. et al. cGMP-grade human iPSC-derived retinalphotoreceptor precursor cells rescue cone photoreceptor damage in non-humanprimates. Stem Cell Res Ther 12, 464 (2021).https://doi.org/10.1186/s13287-021-02539-8
[iv] Media Release 11 October 2021 “A*STAR’S IMCB, RXCELL, NUS, AND SERI COLLABORATETO DEVELOP CELLULAR THERAPEUTICS FOR AGE-RELATED DISEASES” https://www.a-star.edu.sg/docs/librariesprovider19/newsroom/2021/press-release-11102021.pdf
About Edge Capital Asset Management Pte. Ltd.
Edge Capital Asset Management (“Edge Capital”) is a fund management company regulated by the Monetary Authority of Singapore. Edge Capital is the investment manager to Edge Capital Fund SPC, a Cayman segregated portfolio company with various fund strategies. Edge Capital aims to be a fore runner in fund management both in Singapore and the region. Its portfolios are focused to provide exposure into niche areas where investors will benefit from high return multiples. All assets under management are actively managed for risk and towards delivering strong performance for investors.
For enquiries please contact - Email: email@example.com, Tel: +(65) 3150 2316
Important Notes and Disclaimer
Additional information including private placement memorandum, associated appendix and subscription documents are available upon request. The information including projections in this material has been obtained and derived from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, Edge Capital Asset Management Pte. Ltd. or its affiliates and/or subsidiaries (collectively “Edge Capital”) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to Edge Capital. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. Any data discrepancies in this material could be the result of different calculations and/or adjustments. Edge Capital accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither Edge Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent Edge Capital current opinions or judgment as of the date of the material only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or also be affected by changes in exchange rates. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. This material does not constitute an offer to buy or solicitation of an offer to invest, or to procure an investment in or sell any funds or investment vehicles in any jurisdiction in which an offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation and is for information purposes only. Subscriptions to any fund will only be received from professional and accredited investors and investments are accepted only on the basis of the current private placement memorandum and relevant appendix of the fund. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipients of this material must make their own independent decisions regarding an investment into the fund and any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. Funds managed by Edge Capital are currently open for subscription by non-United States of America persons only, unless otherwise stated.